Prediabetes or OverweightNCT07840170
Whole Food Fibers for Support of Key Gut Bacteria for Human Health
A study testing Whole food fiber mixture and inulin in people with Prediabetes or Overweight, run by Purdue University at 1 site in United States.
Trial summary
The purpose of this supplementation study is to understand how whole food fibers may affect gut microbiota composition and overall health. The investigators will enroll up to 24 people in this study. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Prediabetes or Overweight
- What is being tested?
- Whole food fiber mixture and inulin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Nov 2026to 30 Apr 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Overweight or obese, defined as a Body Mass Index (BMI) of 25 to 35 kg/m²
- Prediabetic (HbA1c: 5.7 - 6.3), though otherwise healthy subjects
- 18-65 years age
Who cannot join
- Kidney dysfunction
- Thyroid dysfunction
- Liver dysfunction
- Use of antibiotics in the last four weeks
- Use of probiotics in the last four weeks
- Use of prebiotics in the last four weeks
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Clinical Research Center at Purdue University
West Lafayette, Indiana, 47907
About this study
The purpose of this supplementation study is to understand how whole food fibers may affect gut microbiota composition and overall health. The investigators will enroll up to 24 people in this study. To be eligible, participants need to be between 18 and 65 years old, have a Body Mass Index of 25 to 35 kg/m², be prediabetic (HbA1c: 5.7 - 6.3), be free of any inflammatory bowel disease or any colon-related disease, be free of wheat allergens or intolerance, and not be pregnant or nursing. If participants have any questions about the criteria, they will ask the investigator consenting them. This is a randomized, cross-over, double-blind, clinical trial (RCT) that will last 12 consecutive weeks in total (4 weeks of treatment A + 4 weeks of washout + 4 weeks of treatment B). The order of the treatments will be randomly assigned before the beginning of the study. If proved right, this study will provide a science-based fiber reason why consumption of whole foods constitutes a better dietary approach than the current practice of adding soluble dietary fiber (inulin) alone to modulate gut microbiota for gut and whole-body health.
- Conditions
- Prediabetes or Overweight
- Being tested
- Whole food fiber mixture, inulin
- Keywords
- whole foods, dietary fiber, prebiotics, gut microbiota, gut health
- Medical subject headings
- Prediabetic State, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Whole food fiber mixtureDietary supplement
Participants will consume 2 servings per day of a whole-food fiber-based mixture packaged in the form of a sachet, prepared by an external manufacturer , and diluted in 100 mL of water prior to consumption. Each serving contains 7.5 g of a whole-food fiber mixture (designed by the research team), 0.7 g of flavor (berry, banana, or lemon), 0.2 g of guar gum (thickening agent), 0.5 g citric acid, and 0.1 g stevia.
inulinDietary supplement
Participants will consume 2 servings per day of an inulin packaged in the form of a sachet, prepared by an external manufacturer, and diluted in 100 mL of water prior to consumption. Each serving contains 7.5 g of commercially sourced isolated inulin, 0.7 g of flavor (berry, banana or lemon), 0.2 g of guar gum (thickening agent), 0.5 g citric acid, and 0.1g stevia.
| Study group | Role | What they receive |
|---|---|---|
| Whole food fiber mixture | Experimental | For a duration of 4 weeks, participants will consume 2 servings per day of a whole-food fiber powder mixture designed by the research team. This intervention period will be followed by a 4-week washout period during which participants will not consume any dietary supplements. Receives: Dietary Supplement: Whole food fiber mixture |
| Inulin | Active comparator | For a duration of 4 weeks, participants will consume 2 servings per day of a commercially available Inulin. This intervention period will be followed by a 4-week washout period during which participants will not consume any dietary supplements. Receives: Dietary Supplement: inulin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Colonic butyrogenic Clostridium clusters IV and XIVa
Changes in composition of bacterial taxa belonging to Clostridium clusters IV and XIVa will be assessed following consumption of the whole-food fiber mixture compared with inulin using 16S rRNA gene sequencing of fecal samples.
Measured: Outcomes will be analyzed at the beginning (week 0 and week 8) and end of each supplementation period (week 4 and week 12).
Secondary outcomes (1)
Blood markers of gut and systemic health effects
Mesures in blood of gut metabolites: short-chain fatty acid (SCFAs) concentrations (mM).
Measures of intestinal barrier integrity: zonulin (ng/mL), intestinal fatty acid-binding protein (ng/mL).
Measures of bacterial translocation in the gut: lipopolysaccharide [LPS] (ng/mL), LPS-binding protein (ng/mL).
Measures of systemic inflammatory cytokines: IL-1, IL-6, IL-8, TNF-alpha and IL-10 (pg/mL).
Measure of metabolic health: HOMA-IR.
Measured: Outcomes will be analyzed at the beginning (week 0 and week 8) and end of each supplementation period (week 4 and week 12).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2026
- Study start1 Nov 2026 (estimated)
- Primary completion28 Feb 2027 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prediabetes or OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Purdue University
- Sponsor type
- University, hospital or other
- Collaborators
- Rush University Medical Center
- Responsible party
- Principal investigator, CantuJungles, Purdue University
- Investigators
- Thaisa M Cantu-Jungles, PhD, Principal investigator, Purdue University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07840170
- Sponsor's protocol ID
- IRB-2022-1659
- Other IDs
- 2023-67017-40013, 2023
- Status last verified
- Sep 2026
- First submitted
- 13 Feb 2026
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided